相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Robotic resection for esophageal cancer
Jan-Niclas Kersebaum et al.
EUROPEAN SURGERY-ACTA CHIRURGICA AUSTRIACA (2021)
The real risk of nodal disease in T1 oesophageal adenocarcinoma A systematic review
David P. Mitchell et al.
EUROPEAN SURGERY-ACTA CHIRURGICA AUSTRIACA (2020)
Is fundoplication advisable in repair of para-oesophageal hernia? Little operation or big operation?
Gregory L. Falk et al.
EUROPEAN SURGERY-ACTA CHIRURGICA AUSTRIACA (2020)
Global burden of oesophageal and gastric cancer by histology and subsite in 2018
Melina Arnold et al.
GUT (2020)
The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications
Yuanyuan Zhang et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Alex D. Waldman et al.
NATURE REVIEWS IMMUNOLOGY (2020)
Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019
Pedro Pimentel-Nunes et al.
ENDOSCOPY (2019)
KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer
Ken Kato et al.
FUTURE ONCOLOGY (2019)
A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma
Alexander C. Huang et al.
NATURE MEDICINE (2019)
Variation of Programmed Death Ligand 1 Expression After Platinum-based Neoadjuvant Chemotherapy in Lung Cancer
Lei Guo et al.
JOURNAL OF IMMUNOTHERAPY (2019)
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
Salah-Eddin Al-Batran et al.
LANCET (2019)
Current surgical treatment of esophagogastric junction adenocarcinoma
Shun Zhang et al.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY (2019)
New evidence defining the pathology and pathogenesis of lower esophageal sphincter damage
Parakrama Chandrasoma
EUROPEAN SURGERY-ACTA CHIRURGICA AUSTRIACA (2019)
Drug-induced PD-L1 expression and cell stress response in breast cancer cells can be balanced by drug combination
Yosi Gilad et al.
SCIENTIFIC REPORTS (2019)
History of Esophagogastric Junction Cancer Treatment and Current Surgical Management in Western Countries
Felix Berlth et al.
JOURNAL OF GASTRIC CANCER (2019)
Changes in Expression of Multiple Checkpoint Molecules and Infiltration of Tumor Immune Cells after Neoadjuvant Chemotherapy in Gastric Cancer
Yue Yu et al.
JOURNAL OF CANCER (2019)
Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma
Edwin R. Parra et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2018)
The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers
Kazuki Takada et al.
CLINICAL LUNG CANCER (2018)
PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma
Dagmar Kollmann et al.
ONCOIMMUNOLOGY (2018)
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Xin Yang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Bcl-2 Inhibition to Overcome Resistance to Chemo- and Immunotherapy
Marilina Garcia-Aranda et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC)
S. J. L. Mesnage et al.
ANNALS OF ONCOLOGY (2017)
Endoscopic management of Barrett's esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement
Bas Weusten et al.
ENDOSCOPY (2017)
Perspectives of HER2-targeting in gastric and esophageal cancer
James N. Gerson et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
Expression of Programmed Cell Death Protein 1 by Tumor-Infiltrating Lymphocytes and Tumor Cells is Associated with Advanced Tumor Stage in Patients with Esophageal Adenocarcinoma
Dagmar Kollmann et al.
ANNALS OF SURGICAL ONCOLOGY (2017)
Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational Load Tumor
Rajeev Dhupar et al.
ANNALS OF THORACIC SURGERY (2017)
8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice
Thomas W. Rice et al.
ANNALS OF CARDIOTHORACIC SURGERY (2017)
Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
Lucia Festino et al.
DRUGS (2016)
Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer
S. H. Lim et al.
EUROPEAN JOURNAL OF CANCER (2016)
Programmed death-ligand 1 expression in rectal cancer
G. Jomrich et al.
EUROPEAN SURGERY-ACTA CHIRURGICA AUSTRIACA (2016)
Management of Locally Advanced Adenocarcinoma of the Esophagus and Gastroesophageal Junction: Finally a Consensus
Lawrence Kleinberg et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2015)
Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma
Sarah Derks et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type
Zoran Gatalica et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2014)
Programmed death-1 pathway in cancer and autoimmunity
Ariel Pedoeem et al.
CLINICAL IMMUNOLOGY (2014)
Photodynamic therapy for esophageal carcinoma*
J. Lindenmann et al.
EUROPEAN SURGERY-ACTA CHIRURGICA AUSTRIACA (2011)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Limited surgery for 'early' cancer of the esophagus
A. H. Hoelscher et al.
EUROPEAN SURGERY-ACTA CHIRURGICA AUSTRIACA (2007)
Is immunotherapy a reasonable approach for the treatment of esophageal cancer?
J. Friedl et al.
EUROPEAN SURGERY-ACTA CHIRURGICA AUSTRIACA (2007)
B7-h1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression
J Konishi et al.
CLINICAL CANCER RESEARCH (2004)
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target
RH Thompson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
PD-L2 is a second ligand for PD-I and inhibits T cell activation
Y Latchman et al.
NATURE IMMUNOLOGY (2001)
分享论文
